Prothena Corporation plc Ordinary Shares (PRTA)

FairStock Score: 46/100 — MIXED

Key Financials

Strengths

• Conservative balance sheet with debt-to-equity of just 0.02, providing financial flexibility

Concerns

• Currently unprofitable—sustained losses could lead to dilutive capital raises or balance sheet deterioration
• Revenue declining at 99.0% year-over-year signals potential demand weakness or market share loss
• Weak Piotroski F-Score of 3/9 suggests deteriorating financial quality across multiple dimensions

AI Analysis

Prothena Corporation plc Ordinary Shares is a micro-cap healthcare company valued at $579 million. Revenue stands at $58 million, though the company is currently unprofitable. From a quality standpoint, Prothena shows weak Piotroski F-Score of 3/9 signaling deteriorating fundamentals and Altman Z-Score of 2.5 in the grey zone. Growth dynamics show revenue growing at -99.0% and profit growth of 62.8%. Our composite FairStock Score of 46/100 reflects mixed fundamentals overall. Without profitability, this remains speculative—suitable only for those with high risk tolerance and a long time horizon.

Bull Case

Improving fundamentals and sector tailwinds could drive meaningful earnings growth, compressing the effective multiple for patient investors. Operational leverage in the business model means incremental revenue growth could disproportionately boost bottom-line profitability.

Bear Case

Without a clear path to profitability, continued cash burn forces either dilutive equity raises or debt accumulation that destroys shareholder value. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer